The Medicines Patent Pool (MPP) welcomes the Director-General’s report and supports the call for multisectoral action to address the high burden of NCDs, particularly in line with previous resolutions on strengthening the prevention and control of diabetes and cervical cancer elimination.

MPP is committed to working with all parties to explore opportunities to increase access to quality-assured, affordable medicines in low- and middle-income countries. This may include, for example, GLP-1 receptor agonists for diabetes, obesity, and cardiovascular disease. And immune checkpoint inhibitors for the treatment of various types of cancers, including cervical cancer, are bridging the gap between innovation and equitable access to treatment.

MPP remains determined to work with WHO Member States and other stakeholders to identify priority medicines and facilitate access in low- and middle-income countries through licensing and technology transfer.